Sign up online today & collaborate
or click here to find out more
Investment manager Deepbridge Capital has today announced the £2m funding of 12 seed stage life sciences companies.
Deepbridge raised funds via the Deepbridge Life Sciences SEIS proposition, launched in 2015. The Deepbridge Life Sciences SEIS provides financial advisers and private investors the opportunity to invest in a portfolio of early stage life sciences investments, whilst benefitting from the significant potential tax reliefs available via the Government’s Seed Enterprise Investment Scheme.
The twelve companies to be funded by the Deepbridge Life Sciences SEIS are; Aurio, Beamline Diagnostics, eLucid mHealth, EligoChem, Filisia Interfaces, Ibis Vision, Metix, Parkure, PeptigelDesign, Renephra, Stent Tek and Transcriptogen.
Dr Savvas Neophytou, Partner and Head of Life Sciences, commented:
“We are delighted to have completed investment in 12 new life sciences companies. The addition of these 12 investments, sitting alongside our flagship investments in Sky Medical and Liverpool Chirochem, provides us with a good portfolio with which to grow our ambitions in this sector. We have searched widely for investment opportunities, undertaking due diligence on some 126 companies from across the UK. 39 of those companies were device or life science tools, 28 companies were BioPharma drug discovery and development, 26 were diagnostic technologies, 26 were software and e-health with a further 4 companies engaged in drug delivery. We welcome the 12 new portfolio companies to the Deepbridge family and we look forward to working closely with them to deliver their growth ambitions.”